Month: August 2023

$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to Support Operations into the Second Half of 2024 SOLANA BEACH, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported financial and operating results for the three months ended June 30, 2023 and provided a business update. “During the second quarter we were pleased to announce the achievement of multiple objectives and present new data,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “Notably, based on the very encouraging safety profile from our Phase 1b study, we initiated Phase 2a of our Cancer...

Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical trial at the 60th ERA Congress Initiated Phase 3 ORIGIN 3 clinical trial of atacicept in June for the treatment of IgAN Strong balance sheet expected to fund operations to early 2026BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business updates and financial results for the second quarter ended June 30, 2023. “During the second quarter, we announced positive 36-week data from the Phase 2b ORIGIN trial, which support its potential as a disease-modifying treatment for patients with IgAN,”...

Total Revenue of $33.2 million Up 17.3% YoYillumin Self-Serve Revenue Up 145% QoQ As Client Base Grew 54% (All monetary figures are expressed in thousands of Canadian dollars unless otherwise stated) TORONTO and NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX:ILLM, Nasdaq:ILLM) (“illumin” or the “Company”), a journey advertising technology company that empowers marketers to make smarter decisions about communicating with online consumers, today announced its financial results for the second quarter ended June 30, 2023. Second Quarter 2023 HighlightsSecond quarter 2023 revenue was $33.2 million, an increase of 17.3% year-over-year, and an increase of 25.3% over first quarter 2023 revenue, as we continue to see the benefits of our strategic investments in illumin sales, marketing, and product development. illumin...

Special Meeting of Stockholders Regarding Merger With Samsung Display Co. to Be Held August 31, 2023 HOPEWELL JUNCTION, N.Y., Aug. 10, 2023 (GLOBE NEWSWIRE) — eMagin Corporation, or the “Company,” (NYSE American: EMAN), a U.S.-based leader in the development, design, and manufacture of Active-Matrix OLED microdisplays for high-resolution, AR/VR and other near-eye imaging products, today announced results for its second quarter ended June 30, 2023. As previously announced, the Company has entered into a definitive merger agreement with Samsung Display Co., Ltd. (“Samsung Display”), a subsidiary of Samsung Electronics Co., Ltd. (KRX: 005930) and manufacturer and distributor of display products. Under the terms of the agreement, all outstanding shares of eMagin common stock on a fully diluted basis will be acquired for $2.08 per share...

Phase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) enrollment target has now been surpassed Announced positive clinical data from the completed AQUAx Phase 1 study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX), showing bilaterally treated participants reaching normal levels of whole saliva flow rate by 2 months post-treatment and persisting through the final Month 12 assessment in the studyInitiated Phase 2 randomized, double-blind, placebo-controlled study of AAV2-hAQP1 for the treatment of grade 2/3 RIXWholly-owned gene therapy manufacturing facility in Shannon, Ireland received Commercial MIA Authorization for QC Testing and is the first manufacturing site for gene therapy to receive a commercial license...

Tigris Trial Enrollment Reaches 71 Patients TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2023 and provided a corporate update. During the second quarter, the Company continued to execute on a number of key business initiatives that are targeted at enhancing and accelerating Tigris enrollment. Management is pleased to report positive progress on these initiatives, specifically:During and subsequent to the second quarter the Company enrolled an additional 18 patients, nearly half of which came from new sites opened for enrollment in 2023; 71 patients enrolled to date and the Company continues to close in...

OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company’s progress. “In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL,” said Bill Enright, Vaccitech’s Chief Executive Officer. “Looking ahead, we remain steadfast in our focus on HBV and are eagerly anticipating interim data from our ongoing Phase 2 trials...

Working Capital Increases by $6.8 million RELI Exchange Continuing to Grow its Network of Agency Partners Strategic Plan for Consolidation of Subsidiary Agencies Leading to Enhanced Market Presence Reports 30% Reduction in Loss from Operations for the First Half of 2023 Over Same Period Last Year Company to Host Conference Call Today at 12:00 PM Eastern Time LAKEWOOD, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: RELI; RELIW) (“Reliance”, “we” or the “Company”), today provided a business update and reported financial results for the second quarter ended June 30, 2023. Ezra Beyman, CEO of Reliance, commented, “We are pleased to report a 12% and 21% year-over-year increase in revenue for the second quarter and first half of 2023 respectively, which primarily reflects the organic growth of the...

Strong Sales of $5.5 million alongside Drug Partnering Agreement MISSISSAUGA, Ontario, Aug. 10, 2023 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and YTD fiscal 2023 ended June 30, 2023 (“Q3” and “YTD”), a period in which strong revenues were realized along with a fully-funded partnering of its drug asset Kinlytic® urokinase (“Kinlytic”). Management Discussion Q3 posted revenues of $5.5 million, with continued strength in sales of test ingredients (“Antigens”) and test-controls (“QAPs™”) totaling $4.0 million, but none of sample collection media (“DxTM™”). Revenues in Q3 benefited from the recognition of over $1.3 million of Kinlytic license fees, however this was more than offset by a write-down...

Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due to mitochondrial DNA (mtDNA) defects, anticipated in 4Q23 IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a business update. “We are looking forward to topline results from our pivotal STRIDE study expected in the fourth quarter this year and continue to be encouraged by the high roll over rate of PMM patients into our open label extension STRIDE AHEAD study, where we have enrolled over 130 patients,” said...